Creative Medical Technology Holdings Inc Dossier - Source-backed chat

Creative Medical Technology Holdings Inc

CELZNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.63

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.94Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $7.1M

Enterprise Value −$1.6M

Shares Outstanding 6.6M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company transitioning from execution risk to a data-driven value creation phase. The company's proprietary perinatal tissue-derived cell therapy platform, AlloStem® (CELZ-201 / olastrocel), has demonstrated strong safety and early efficacy signals in treating chronic lower back pain (ADAPT trial) and Type 1 diabetes (CREATE-1 trial). The recent breakthrough 93% response rate in its cell-free Ultrasome™ knee osteoarthritis program highlights the scalability of its platform into high-volume, minimally invasive regenerative therapies. While the company operates with minimal revenue and relies on external financing, its prudent capital management, lack of debt, and integration of AI-driven biodefense initiatives (Project PHOENIX) provide a highly asymmetric risk-reward profile for biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$20.00

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.7620%

The bear case is triggered by clinical delays, safety concerns raised during long-term follow-ups, or a failure to secure strategic partnerships. This would force the company to raise capital through highly dilutive equity offerings or structured warrant adjustments, depressing the share price as cash reserves dwindle.

Base CaseCentral scenario

$9.2755%

The base case assumes steady clinical progress across the CELZ-201 platform, with the company successfully completing the follow-up phase of the ADAPT trial and initiating late-stage regulatory discussions with the FDA under its Fast Track designation. The company maintains its cash runway through disciplined R&D spending and opportunistic warrant exercises, while slowly expanding its AI-driven veteran registry.

Bull CaseUpside scenario

$15.4725%

The bull case is driven by positive final topline data from the FDA-cleared ADAPT trial for chronic lower back pain, leading to a lucrative out-licensing or co-development partnership with a major pharmaceutical company. Additionally, rapid enrollment in Project PHOENIX secures non-dilutive federal biodefense funding, while the cell-free Ultrasome™ platform enters Phase I/II trials with continued industry-leading efficacy, driving the stock toward historical highs.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Validated regenerative platforms including AlloStem® (cell-based) and Ultrasome™ (cell-free) targeting multi-billion-dollar markets in orthopedics and immunotherapy.
FDA Fast Track designation for CELZ-201-DDT, enabling accelerated regulatory interactions and rolling BLA submissions.
Strong intellectual property portfolio with over 60 patents and pending applications, alongside WHO-approved International Nonproprietary Names (olastrocel and etaroleucel).
Integration of AI and multi-omics (Project PHOENIX) to optimize therapeutic precision and target non-dilutive federal biodefense contracts.

Key Investment Risks

Clinical-stage risk with recurring operating losses ($6.1 million in FY 2025) and negligible commercial revenues.
High reliance on capital markets or external financing to fund late-stage clinical trials, presenting dilution risk to existing shareholders.
Potential share price pressure from the resale of shares registered under warrant inducement agreements.

Thesis Invalidation Triggers

Failure of CELZ-201 to meet primary safety or efficacy endpoints in the final ADAPT trial data readout.
Inability to secure a strategic development partner or non-dilutive funding within the next 12-18 months, leading to severe capital constraints.
Regulatory setbacks or clinical holds imposed by the FDA on ongoing trials.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.